

**2<sup>nd</sup> Edition**

# **Immunization** **in** **Clinical Practice**



*Editors*

**Naveen Thacker**  
**Nitin K Shah**

*Academic Editors*  
**Abhay K Shah**  
**Alok Gupta**

*Foreword*  
**Pramod Jog**



# Contents

---

## Section I Basics in Immunization

- 1. General Immunology and Principles of Vaccination** 3  
*Suhas V Prabhu, Rajiv Kumar Bansal*  
Immune System 3; Types of Immunity 4; Humoral Immune Response 5  
Antigen-presenting Cells 5; Cell-mediated Immunity 6  
Role of Various Types of Immune Responses in Infections 6  
Passive Immunity 7; Active Immunity 8  
Vaccines 9; Immune Memory 9; Immunomodulation 10
- 2. General Guidelines for Vaccination** 12  
*Abhay K Shah, Monjori Mitra, Nupur Ganguly*  
Staff Education 12; Patient Preparation and Care 12; Vaccine Preparation 13  
Vaccine Administration 14  
Immunization in Special Situations 16; Documentation 17  
Vaccine Storage and Handling 17; Safe Injection Practices and Infection Control 17  
Adverse Events Following Immunization 18
- 3. Immunization Schedules** 20  
*Baldev S Prajapati, Rajal B Prajapati*  
Principles of Vaccine Scheduling 20; Nature of Vaccine 20  
Immunogenicity and Potential Interference by Passively  
Transferred Maternal Antibodies 21  
Local Epidemiology of the Disease 21; Changing Epidemiology of the Disease 22  
Spacing of Multiple Doses of the Same Antigen 22  
Simultaneous Administration of Vaccines 22  
Combination Vaccines 22; Vaccine Failure 23  
Developing and Developed Countries 23; Updating the Subject 23  
Practical Training 23; WHO and Immunization Programs 23  
National Immunization Schedule 24; IAP Immunization Schedule 24  
International Immunization Schedules 24; Immunization in Adolescents 24  
Immunization Schedule for an Unimmunized Child 24
- 4. Storage of Vaccines and Maintenance of Cold Chain** 37  
*Digant D Shastri, Satish Kumar Gupta*  
Why Should We be Concerned about Proper Vaccine Storage? 37; Cold Chain 37  
Storage of Vaccines 38; Levels of Vaccine Storage 39; Cold Boxes (Coolers) 40  
Vaccine Carriers 40; Conditioning of ICE Packs 41  
Tips for Better Vaccine Storage in Domestic Refrigerators 42  
Purpose-built Vaccine Refrigerator 44; Cold Chain Temperature Monitoring 45  
Personnel 47; Protocols 47
- 5. Adverse Events Following Immunization** 49  
*Jyoti Joshi, Narendra K Arora*  
Vaccine Reactions 50; Reporting and Investigations 53; Causality Assessment 56

**6. Safe Injection Practices****58***Divya Dave, Niranjan Shendurnikar*

What is an Injection? 58; What is a Safe Injection? 58

Why are Injections so Popular? 58; Magnitude of the Problem 59

What can be done to Promote Safe and Appropriate Use of Injections? 60

Recommended Routes of Injection and Needle Length 61; Injection Devices 63

What is the Progress? 63; Injection Safety Guidelines 64; Waste Disposal 64

**Section II Vaccines Widely Used in Children****7. Immunization Against Tuberculosis****69***Ankur Kumar, Surjit Singh*

Epidemiology of Tuberculosis 69; Prevention of the Disease 70

BCG Vaccination 71; Revaccination 74; Newer Vaccines for Tuberculosis 75

**8. Diphtheria, Pertussis and Tetanus Vaccines****85***Vipin Vashishtha, HP Singh*

Epidemiology 85; Diphtheria, Pertussis and Tetanus (DPT) Vaccines 85

**9. Immunization Against Poliomyelitis****92***T Jacob John, Naveen Thacker*

Pathogen 92; Host 93; Mode of Transmission 93

Morbidity Including Clinical Spectrum 94; Disease Mortality 94

Vaccines Against Poliomyelitis 94; Vaccine Efficacy 97; Combination Vaccines 98

Vaccine Schedule 98; Vaccine Storage, Handling and Inoculation 99

Adverse Reactions Following Vaccination 99

Contraindications 100; Special Considerations 100

**10. Immunization Against Measles, Mumps and Rubella****101***Satish Pandya*

Measles 101; Clinical Features 101; Effect on Immunity 101

Complications 102; Virology 102; Epidemiology 102

Passive Immunization 102; Active Immunization 103; Vaccine Strains 103

Vaccine Composition 103; Dosage and Route of Administration 103

Stability of Vaccine 103; Results of Vaccination 103; Effectiveness of Protection 104

Rubella 109; Clinical Features 109; Virology 110; Epidemiology 110

Significance as a Public Health Problem 111; Indian Data 111

Passive Immunization 111; Active Immunization 111; Vaccine Strains 111

Dosage and Route of Administration 111; Stability of Vaccine 111

Combination with Measles and Mumps 111; Results of Vaccination 112

Mumps 115; Clinical Features 115; Virology 116; Epidemiology 116

Passive Immunization 116; Active Immunization 116; Vaccine Strains 117

Dosage, Route of Administration and Composition 117; Stability of Vaccine 117

Combinations Including Mumps Vaccine 117; Vaccine Use 117

Correlates of Immunity 117; Persistence of Antibodies 118

Protective Efficacy and Effectiveness 118

Simultaneous Administration with Other Vaccines 118; Adverse Events 118

Precautions and Contraindications 119; Epidemiologic Effects of Vaccination 119

Indian Perspective on MMR Vaccine 119

<b>11. Immunization Against Hepatitis B</b>	<b>122</b>
<i>Anil K Dutta, Late Panna Choudhury, Ashok Kumar Dutta, Priya Perriera</i>	
Epidemiology 122; Hepatitis B—Transmission 122; Prevention of Hepatitis B 124	
Vaccine Efficacy 129; Adverse Events 129; Contraindications to Vaccination 129	
Vaccine Escape Mutants 129; Recommendations for Vaccination 130	
World Health Organization (WHO) Recommendations 130	
Public Health Importance of Hepatitis B Vaccination 131	
<b>12. Immunization Against Typhoid Fever</b>	<b>138</b>
<i>Abhay K Shah, Vijay Yewale, Rohit Agrawal</i>	
Burden of Disease 138	
<b>13. Immunization Against <i>Haemophilus influenzae</i> Type B</b>	<b>148</b>
<i>Pravin Mehta, Jaydeep Choudhury</i>	
Disease Spectrum 148; Disease Transmission 148	
Prevention of Hib Disease 149; Hib Vaccine 149	
<b>14. Immunization Against Hepatitis A</b>	<b>153</b>
<i>Nitin K Shah, Ashish Bavdekar</i>	
Epidemiology 153; Clinical Manifestations 155	
Passive Immunization 155; Active Immunization 156	
<b>15. Varicella Vaccine</b>	<b>163</b>
<i>MR Lokeshwar, Tanu Singhal</i>	
Mode of Transmission 164; Clinical Spectrum and Outcome 164;	
Prevention of Varicella 164; Recommendations for Use 168;	
Vaccination in Special Situations 168; Passive Protection with Varicella	
Zoster Immunoglobulin (VZIG) 169	
<b>16. Rotavirus Vaccines</b>	<b>171</b>
<i>SG Kasi, Pramod Jog</i>	
Disease Burden 171; Virus 171; Rotavirus Vaccines 172	
Impact of Rotavirus Vaccines 173; Serotype Replacement 174	
Vaccine Safety 174; Rotavac: The 116E Oral Rotavirus Vaccine 174	
Economic Burden of Rotavirus and Cost-effectiveness of a National	
Rotavirus Vaccination Program 175	
<b>17. Influenza Vaccines: Current Perspectives</b>	<b>178</b>
<i>S Balasubramaniam, Abhay K Shah, Raj Kumar</i>	
Global Influenza Disease Burden 178; Burden of Influenza Disease in India 179	
Influenza Disease Surveillance in India 179; Influenza Vaccines 179	
Vaccine Immunogenicity 181; Adverse Events 182	
Contraindications and Precautions 182; IAP Recommendations 183	
Recent Pandemic in 2014 183; Vaccination Timing in India 184	
Recommended Vaccine Strains for 2015–2016 184	
<b>18. Human Papilloma Virus (HPV) Vaccines</b>	<b>188</b>
<i>Anupam Sachdeva, Raju C Shah</i>	
Background 188; Burden of Disease Caused by HPV 188	
Prevention of Cervical Cancer: Screening or Vaccination 189; Pathogenesis 189	

Protective Immunity 189; HPV Vaccines 190; Quadrivalent Vaccine (HPV4) 191  
 Bivalent Vaccine (HPV2) 191; Efficacy Against Genital Warts 192  
 Safety of HPV Vaccines 192; Recommendations for Use 192; Dose and Schedule 193  
 Catch-up Vaccination 193; Evidence and Justification 194

## **19. Immunization Against *Streptococcus pneumoniae* 198**

*Nitin K Shah, Sanjay Srirampur, Pritesh Nagar*

Epidemiology 198; Disease Morbidity Including Clinical Spectrum 199  
 Disease Mortality 199; Drug Resistance 200; Prevention of Disease 200

# **Section III Immunization in Special Circumstances**

## **20. Dengue Vaccine 213**

*Sharad Agarkhedkar, T Anh Wartel, Josemund Menezes*

Prevention 214; Trials for Vaccine 214; Acknowledgments and Disclosures 217

## **21. Immunization of Children in Special Situations 218**

*Uday Bodhankar, Sheikh Minhaj Ahmed*

Preterm and Low-birth-weight Infants 218; Missed Immunization 219  
 Adolescent Immunization 220; Adopted Child 220  
 Children Residing in Institutions 220; Children Residing in Refugee Camps 221  
 Immunosuppressed Child 221; Immunization to Children on Steroid Therapy 223  
 Immunization in Children with Malignancy 224  
 Immunization in Transplant Recipients 224; Immunization in Asplenic Children 225  
 Immunization in the Child with Coagulopathy 226  
 Immunization in Children with Progressive Neurological Disorder 226  
 Foreign Travel 226; Postexposure Vaccination 227  
 Immunization During Epidemics 227

## **22. Immunization Against *Neisseria meningitidis* 230**

*Anuradha Bose, Shyam Kukreja*

Bacteriology 230; Risk Factors 230; Pathogenesis 230  
 Clinical Disease and Presentation 231; Immunity to Meningococcal Disease 231  
 Active Immunization 231; History of Meningococcal Vaccine Development 231

## **23. Immunization Against Rabies 235**

*Ritabrata Kundu, P Ramachandran*

Epidemiology 236; Virus 236; Pathogenicity 237; Reservoir 237  
 Modes of Transmission 237; Clinical Presentation of Rabies in Human 237  
 Prevention of Rabies 238; Rabies Immunoglobulin 239; Antirabies Vaccines 240

## **24. Immunization Against Japanese Encephalitis 244**

*Raj Shankar Ghosh, Devendra Khandait*

Geography 244; Disease Burden 245; Epidemiology 246  
 Japanese Encephalitis Virus 246; Clinical Presentation of Japanese Encephalitis 246  
 Treatment and Management 246; Immunity 247; Laboratory Investigations 247  
 Case Classification of Suspected Japanese Encephalitis 249  
 Japanese Encephalitis Control 249; Japanese Encephalitis Vaccines 249

Vaccine Interchangeability	253
Japanese Encephalitis Vaccination in Special Risk Groups	253
Impact of Japanese Encephalitis Vaccines	253
WHO Recommendations on Japanese Encephalitis Vaccines	253
Reactive Vaccinations During Outbreaks	254
Japanese Encephalitis Vaccination for Special Risk Groups	254
Japanese Encephalitis Vaccination Program in India	254

## **25. Immunization of Adolescents 258**

*Preeti M Galagali*

Importance of Adolescent Immunization	258;	Adolescent Immunization Schedule	259
Human Papillomavirus Vaccines	261		
Tetanus and Diphtheria Toxoids and Acellular Pertussis (TDAP) Vaccine	261		
Catch-up Vaccinations	261;	Vaccines in Special Circumstances	262
Vaccines for Adolescent Travellers	264;	Vaccines for Pregnant Adolescents	264
Barriers to Adolescent Immunization	265;	Practice Points for Adolescent Vaccination	267

## **Section IV Future in Vaccinology**

## **26. Combination Vaccines 271**

*Sanjay Gandhi, Shailesh Mehta*

What is a Combination Vaccine?	271;	Why Combination Vaccines?	271
Efficacy of Combination Vaccines	271;	Safety of Combination Vaccines	276
Which Combination Vaccine Available?	276;	Issues with Combination Vaccines?	277

## **27. New Technologies and Future Vaccines 278**

*Suresh Jadhav, Hemant Khanna*

Evolution of Vaccine Technologies	278;	HIV	287
-----------------------------------	------	-----	-----

## **28. Newer Vaccine Delivery Systems and Newer Technologies for Vaccine Delivery 305**

*Alagiriswamy Parthasarathy, Hitt Sharma*

Newer Vaccine Delivery Systems	305;	Newer Technologies for Vaccine Delivery	312
--------------------------------	------	---	-----

## **29. Immunization Resources on Internet 316**

*Sudhanshu Pandey, Alok Gupta*

## **30. VPD Surveillance and Integrated Disease Surveillance 318**

*Ashish Pathak, Deep Thacker*

Background	318;	Why VPD Surveillance is Necessary	318
Surveillance: Terminologies	318;	Current Status of VPD Surveillance in India	319
World Health Organization: National Polio Surveillance Project Supported Surveillance Systems	319		
IDSURV: An Innovative Project to Report Infectious Diseases	319		
Conclusions and the Need of the Hour	321		

# CHAPTER 3

## Immunization Schedules

*Baldev S Prajapati, Rajal B Prajapati*

### INTRODUCTION

Immunization is one of the most cost-effective health interventions known to mankind. It is also true that immunization is the most successful, single, child survival strategy to date. Immunization schedules are the basic framework for the delivery of vaccines to individuals as well as the community as a whole. No single schedule is applicable to all countries or the communities of the world, as immunization schedule has to be framed according to the needs of the individual situation. Therefore, immunization schedule will vary from country to country and from time to time. Thus, there are numbers of immunization schedules, each one having its own advantages and disadvantages. A well-planned immunization schedule should be epidemiologically relevant, immunologically competent, technically feasible, economically viable and socioculturally acceptable.

Many factors are considered while preparing the recommendations and schedules for successful vaccination program in the country. These include epidemiology of the disease, age-specific morbidity and mortality, vaccine immunogenicity, efficacy and effectiveness, risks of vaccine-related adverse reactions, cost effectiveness, health service infrastructure, etc. In order to choose vaccines for vaccination program at government funding, not only

disease burden but their implications should also be known. For government programs, usually it is cost first, efficacy next and safety last. For an individual, it is safety first, efficacy next and cost last. Though what is not in the best interest of the individual cannot be in the best interest of community and what is in the best interest of the community is also in the best interest of the individual. In the past two decades, many new vaccines have developed, vaccine schedule is undergoing rapid changes and has become more complex. It often becomes a matter of debate what is the best schedule, but the knowledge of principles that go behind making each schedule will help pediatricians to build an informed opinion.

### PRINCIPLES OF VACCINE SCHEDULING

Vaccines are recommended for individuals of the youngest age group at risk of experiencing the disease. Optimal response to a vaccine depends upon multiple factors. These include the following.

### NATURE OF VACCINE

Vaccines consist of whole inactivated micro-organisms [e.g. injectable polio vaccine (IPV), hepatitis A], parts of organisms (e.g. acellular



pertussis, human papilloma virus (HPV), hepatitis B virus (HBV), polysaccharide capsules (e.g. pneumococcal and meningococcal polysaccharide vaccines), polysaccharide capsules conjugated to protein carrier [e.g. *Haemophilus influenzae* type b (Hib), pneumococcal and meningococcal conjugate vaccines], live attenuated microorganisms (measles, mumps, rubella, varicella, oral polio vaccine (OPV), rotavirus and live influenza vaccines) and toxoids (tetanus, diphtheria). Attenuated vaccines are prepared by nullifying or minimizing pathogenicity (capacity of producing disease) of the organism and maintaining or enhancing its immunogenicity (capacity of producing antibodies).

Certain vaccines (inactivated vaccines, toxoids, recombinant subunit and polysaccharide conjugate vaccines) require administration of more than two doses for development of an adequate and persisting antibody response. Toxoids (tetanus and diphtheria) require periodic reinforcement or booster dose to maintain protective antibody concentrations. Unconjugated polysaccharide vaccines do not induce T cell memory and hence repeated doses do not produce substantial boosting. However, when conjugated with a protein carrier, the effectiveness of polysaccharide vaccines improves by inducing T cell-dependent immunity. Live attenuated virus vaccines stimulate both cell mediated as well as humoral immunity and, hence, usually can induce prolonged, often lifelong immunity, even if antibody titers decline as time progresses. Subsequent exposure to infection leads to a rapid anamnestic antibody response.

### **IMMUNOGENICITY AND POTENTIAL INTERFERENCE BY PASSIVELY TRANSFERRED MATERNAL ANTIBODIES**

The timing of the first immunization is a compromise between the developing immunity by the infant's immune system and the risk of infection. Maternal transplacental IgG

antibodies are protective for the first few months of life. In early infancy, the protection is partial for some diseases, such as pertussis, and satisfactory against others such as measles. The production of a satisfactory primary antigen response is vital, unless this is achieved, subsequent vaccines will not produce adequate recall response for effective protection.

The immune response of the vaccine is mediated by either humoral or cell-mediated immunity (CMI) or both. Some of the vaccines can stimulate immune system and can protect the child, which is the important factor for consideration while preparing the immunization schedule. Bacillus Calmette–Guerin (BCG), oral polio vaccine (OPV) and hepatitis B virus (HBV) vaccines can be given at birth. The BCG elicits a CMI and maternal antibodies do not interfere with CMI. Maternal antibodies present in baby against OPV have weak inhibitory effect and, therefore, OPV can establish local gut infection in a significant proportion of recipients. HBV is strongly immunogenic and can overcome the effect of maternal antibodies. Live measles and measles, mumps, and rubella (MMR) vaccines are inhibited by maternal antibodies till the age of 9 to 12 months.

### **LOCAL EPIDEMIOLOGY OF THE DISEASE**

The optimal age for starting immunization depends upon both immunological maturity and local disease epidemiology. In countries like India, where tuberculosis and poliomyelitis may affect young children, immunization should be started soon after birth. In countries where pertussis is still common, the vaccine as diphtheria, pertussis, and tetanus (DPT) should be given in early infancy since pertussis in young infants has greater morbidity and mortality. When measles is a great threat, vaccine should be given early, despite the compromised response to it. In developed countries, measles vaccination may be deferred till the age of 12 to 15 months, since chances of early infection are less and the measles vaccine offers optimal response after the age of



12 months. In developing countries like ours, the World Health Organization (WHO) recommends measles vaccine between 9 and 12 months. It may be given earliest at the age of 6 months in high-risk situations. In addition to the WHO schedule, other available vaccines are recommended in specific regions, for example, Japanese encephalitis vaccine in hyperendemic areas.

Once any vaccine is available, before recommending it for a specific region or country, the disease epidemiology is studied. Once it shows existence of disease in community and significant disease burden, it is recommended for routine vaccination.

## CHANGING EPIDEMIOLOGY OF THE DISEASE

With effective vaccination program and good coverage of vaccination in the community, there is a shift of the disease to the right in the age group affected by some vaccine preventable diseases. It has been observed in our country that now measles is affecting older children, chickenpox is also seen in adolescents and adults with life-threatening central nervous system (CNS) complications and whooping cough is seen in adults too. These changes indicate modifications in immunization schedules, extending age of vaccination in older children and even in adults.

## SPACING OF MULTIPLE DOSES OF THE SAME ANTIGEN

Studies have shown that the recommended age of starting and the interval between doses of multidose antigens provide optimal protection or have the best evidence of efficacy. Vaccine doses should not be administered at intervals less than the minimum intervals or earlier than the minimum age. If vaccine doses are administered at interval less than the minimum interval or at younger age than the minimum age, a suboptimal immune response can ensue. However, administering a dose, a limited

number of days earlier than the minimum interval or age is unlikely to have a substantially negative effect on the immune response to the dose. Therefore, it is recommended that vaccine dose administered <4 days before the minimum interval can be counted as valid, the only exception being the rabies vaccine.

There should be a minimum interval of 4 weeks between 2 doses of the same vaccine or between two different vaccines for optimum immunological response. In fact, increasing the interval of 8 weeks increases the concentration of antibody. However, due to some logistic reasons and to complete the immunization before the vulnerable age of the child for the disease, most of our immunization schedules are with interval of 4 weeks duration.

## SIMULTANEOUS ADMINISTRATION OF VACCINES

The current vaccines which are used in children do not have significant interference with each other and hence several antigens can be given simultaneously. Simultaneous administration of all vaccines for which a child is eligible increases the probability that child will be fully immunized at appropriate age, as administering antigens at different times would result in a delay in protection for the deferred components. The simultaneous administration of live and inactivated vaccines have similar seroconversion rates as observed when they are administered at different times. Routinely, simultaneous administration of all vaccines is recommended for children who are of the appropriate age to receive them and for whom no specific contraindications exist at the time of visit.

## COMBINATION VACCINES

The use of combination vaccines can reduce the number of pricks required at a single visit. The use of licensed combination vaccines is preferred over separate injections of their equivalent component vaccines.

## VACCINE FAILURE

About 95% of recipients of a single dose of MMR vaccine develop protective antibody within 2 weeks of the dose. However, 5% of recipients, fail to respond to single dose and hence a second dose is recommended, since majority of vaccines exhibiting primary vaccine failure respond to the second dose. Similarly, a second dose of varicella is recommended at 4 to 6 years of age with the first dose at the age of 12 to 15 months of age to prevent breakthrough varicella. It is not clear whether breakthrough varicella occurs due to primary vaccine failure or due to waning immunity.

## DEVELOPING AND DEVELOPED COUNTRIES

In developing countries like ours, booster immunization schedules present financial and logistic problems, so the main emphasis is on primary immunization as a part of basic health care. In India, injectable polio vaccine is yet to be incorporated in the national immunization schedule due to such reasons. Recently, Hepatitis B and Hib vaccines are included in our national immunization schedule.

## UPDATING THE SUBJECT

A simple immunization schedule should be used. The frequent changes are not desirable. The guidelines should be available for staff and a simplified version for parents. All those involved in immunization program should be trained and new information should be disseminated quickly. The practical issues of the staff and parents should be solved immediately. The publications in question-answer format are more useful and easily accepted by the people.

## PRACTICAL TRAINING

Practical training is very useful for successful immunization program. The people involved in immunization should be trained for practical aspects such as scientific information

regarding the vaccines, care of vaccines, correct administration of vaccines, maintenance of equipment, and cold chain. They should be trained how to prepare and conduct an immunization session or immunization clinic. Periodic evaluation of an immunization program at different levels is important.

## WHO AND IMMUNIZATION PROGRAMS

- Expanded Program of Immunization (EPI) was launched by the WHO in 1974 with the goal of reducing morbidity and mortality from six target diseases (tuberculosis, poliomyelitis, diphtheria, pertussis, tetanus and measles) by providing immunization services to all children less than 5 years old and pregnant women. The vaccines included were BCG, DPT, OPV, measles and TT.
- Universal Childhood Immunization (UCI) was adopted by the WHO. This program became universal instead of earlier target of 85% coverage of immunization as in the EPI. Special efforts were made to initiate research for understanding the epidemiology of the disease, development of newer vaccines and vaccine production technology.
- Child Vaccine Initiative (CVI) was implemented in 1991 after a summit for children in Washington DC in 1990. In the summit, the success of EPI was commemorated in achieving a global coverage of 80% with the six vaccines, and the achievement of UCI was highlighted. The aim was to enhance protection of children against all preventable infectious diseases by promoting newer vaccines and vaccine production technology.
- Global Program on Vaccination (GPV) was launched by the WHO in 1993. It was combination of EPI, UCI and CVI. Its main aims were eradication of polio, elimination of neonatal tetanus and prevention of mortality due to measles. **Table 3.1** shows the details of schedule advocated by the WHO.
- Global Alliance for Vaccines and Immunization (GAVI) replaced CVI in 1999. The

objectives of this program are improving access to sustainable immunization services, expanding the use of all existing safe and cost-effective vaccines, accelerating the development and introduction of new vaccines, accelerating research and development efforts for vaccines and related products and making immunization coverage a centerpiece in the design and assessment of international development efforts.

### NATIONAL IMMUNIZATION SCHEDULE

- In India, EPI was launched in 1978 with the typhoid vaccine replacing measles.
- Unfortunately, the coverage of EPI was very low. In view of this, a revised strategy, Universal Immunization Program (UIP) was launched in 1985 to achieve target immunization goals in a phased and planned manner. The target was infants below 1 year of age, who were vaccinated against the target diseases as well as pregnant women who received TT. The aim was to achieve 100% coverage of all pregnant women and at least 85% of infants.

The immunization services were to be provided through the existing health care delivery system such as maternal and child health (MCH) centers, subcenters, primary health centers, dispensaries, hospitals, Integrated Child Development Services (ICDS) units, etc. It was further incorporated into the "Child Survival and Safe Motherhood (CSSM) in 1992 and the Reproductive and Child Health Program (RCH) in 1997.

This immunization schedule was devised taking into consideration the epidemiological profile of the childhood diseases which cause significant morbidity and mortality in India, as well as financial resources available, logistics, operational feasibility, availability and cost effectiveness of the vaccines. It has undergone time-to-time modifications as required. The latest one is given in **Table 3.1**

### IAP IMMUNIZATION SCHEDULE

In view of data available on various vaccine preventable diseases and the availability of several vaccines, Advisory Committee on Vaccination and Immunization Practice (ACVIP) recommends the schedule as shown in **Tables 3.2 and 3.3**.

### INTERNATIONAL IMMUNIZATION SCHEDULES

In the United States, recommendations for childhood immunization are formulated by two committees, the Advisory Committee on Immunization Practices (ACIP) of the Centers for Disease Control and Prevention (CDC) and the American Academy of Pediatrics (AAP) committee on infectious diseases. These two committees along with American Academy of Family Physicians issue an annual national schedule for routinely recommended childhood vaccinations (**Table 3.4**). The immunization schedule currently being implemented in the United Kingdom is given in **Table 3.5**.

### IMMUNIZATION IN ADOLESCENTS

Immune protection induced by vaccines given during infancy wanes over the years. It leads to higher incidence of vaccine preventable diseases in adolescents and adults with increasing risk of complications. Recently, vaccines have been modified and developed suitable for administering to adolescents offering protection against many diseases. IAP ACVIP recommends vaccines for adolescents as shown in **Tables 3.6 to 3.9**.

### IMMUNIZATION SCHEDULE FOR AN UNIMMUNIZED CHILD

The immunization schedule for an unimmunized child depends upon the age of presentation. The reasons for child remaining unimmunized or partially immunized should be looked into and the parents should be counseled

**Table 3.1** Vaccination schedule under Universal Immunization Program (UIP) in India, 2013

Vaccine	When to give	Dose	Route	Site
<i>For pregnant women</i>				
TT-1	Early in pregnancy	0.5 mL	Intramuscular	Upper arm
TT-2	4 weeks after TT-1*	0.5 mL	Intramuscular	Upper arm
TT- booster	If received 2 TT doses in a pregnancy within the last 3 years	0.5 mL	Intramuscular	Upper arm
<i>For infants</i>				
BCG	At birth or as early as possible till one year of age	0.1 mL (0.05 mL until 1 month of age)	Intradermal	Left upper arm
Hepatitis B birth dose	At birth or as early as possible within 24 hours	0.5 mL	Intramuscular	Anterolateral side of mid thigh
OPV Zero dose	At birth or as early as possible within the 15 days	2 drops	Oral	Oral
OPV 1, 2 and 3	At 6, 10 and 14 weeks	2 drops	Oral	Oral
DPT 1, 2 and 3		0.5 mL	Intramuscular	Anterolateral side of mid thigh
Hepatitis B 1, 2, and 3		0.5 mL	Intramuscular	Anterolateral side of mid thigh
HIB 1, 2 and 3		0.5 mL	Intramuscular	Anterolateral side of mid thigh
Measles 1st dose	9 completed months – 12 months (give up to 5 years if not received at 9–12 months age)	0.5 mL	Subcutaneous	Right upper arm
JE 1st dose**	9 completed months	0.5 mL	Subcutaneous	Left upper arm
<i>For children and adolescents</i>				
DPT booster	16–24 months	0.5 mL	Intramuscular	Anterolateral side of mid thigh
OPV booster	16–24 months	2 drops	Oral	Oral
Measles 2nd	16–24 months	0.5 mL	Subcutaneous	Right upper arm
Rubella***	16–24 months Adolescent girls	0.5 mL	Subcutaneous	Right upper arm
JE 2 <sup>nd</sup> dose	16–24 months with DPT/OPV booster	0.5 mL	Subcutaneous	Left upper arm
DPT booster 2	5–7 years	0.5 mL	Intramuscular	Upper arm
TT	10 years and 16 years	0.5 mL	Intramuscular	Upper arm
Vitamin A****				

\* Give TT-2 or booster doses before 36 weeks of pregnancy. However, give these even if more than 36 weeks have passed. Give TT to a woman in labor, if she has not previously received TT.

\*\* JE vaccine (SA 14–14-2) is given in selected endemic districts, after the campaign is over in that district.

\*\*\* Rubella vaccine will be given as part of measles 2nd dose

\*\*\*\* The 2nd to 9th dose of Vitamin A can be administered to children 1–5 years old during biannual rounds, in collaboration with ICDS (Integrated Child Development Services).

**Table 3.2** IAP Immunization Timetable, 2014*I. IAP recommended vaccines for routine use*

Age (completed weeks/ months/years)	Vaccines	Comments
Birth	BCG OPV 0 Hep – B 1	Administer these vaccines to all newborns before hospital discharge
6 weeks	DTwP 1 IPV 1 Hep – B 2 Hib 1 Rotavirus 1 PCV 1	<b>DTP:</b> <ul style="list-style-type: none"> <li>DTaP vaccine/combinations should preferably be avoided for the primary series</li> <li>DTaP vaccine/combinations should be preferred in certain specific circumstances/conditions only</li> <li>No need of repeating/giving additional doses of whole-cell pertussis (wP) vaccine to a child who has earlier completed the primary schedule with acellular pertussis (aP) vaccine-containing products</li> </ul> <b>Polio:</b> <ul style="list-style-type: none"> <li>All doses of IPV may be replaced with OPV if administration of the former is unfeasible</li> <li>Additional doses of OPV on all supplementary immunization activities (SIAs)</li> <li>Two doses of IPV instead of 3 for primary series if started at 8 weeks, interval between the doses</li> <li>No child should leave the facility without polio immunization (IPV or OPV), if indicated by the schedule</li> </ul> <b>Rotavirus:</b> <ul style="list-style-type: none"> <li>2 doses of RV1 and 3 doses of RV5</li> <li>RV1 should be employed in 10 and 14 week schedule, instead of 6 and 10 week schedule</li> <li>10 and 14 week schedule of RV1 is found to be far more immunogenic than existing 6 and 10 week schedule</li> </ul>
10 weeks	DTwP 2 IPV 2 Hib 2 *Rotavirus 2 PCV 2	<b>Rotavirus:</b> <ul style="list-style-type: none"> <li>If RV1 is chosen, then the first dose should be given at 10 weeks</li> </ul>
14 weeks	DTwP 3 IPV 3 Hib 3 *Rotavirus 3 PCV 3	<b>Rotavirus:</b> <ul style="list-style-type: none"> <li>Only 2 doses of RV1 are recommended at present</li> <li>If RV1 is chosen, then the 2nd dose should be given at 14 weeks</li> </ul>
6 months	OPV1 Hep – B3	<b>Hepatitis B:</b> The final (third or fourth) dose in the Hep B vaccine series should be administered no earlier than age 24 weeks and at least 16 weeks after the first dose

Contd...

Contd...

I. IAP recommended vaccines for routine use		
Age (completed weeks/ months/years)	Vaccines	Comments
9 months	OPV2 MMR-1	<b>MMR:</b> Measles-containing vaccine ideally should not be administered before completing 270 days or 9 months of life The 2nd dose must follow in 2nd year of life No need to give stand-alone measles vaccine
9–12 months	Typhoid Conjugate Vaccine	<ul style="list-style-type: none"> <li>Currently, two typhoid conjugate vaccines, Typbar—TCV and PedaTyph available in Indian market</li> <li>PedaTyph is not yet approved; the recommendation is applicable to Typbar—TCV only</li> <li>An interval of at least 4 weeks with the MMR vaccine should be maintained while administering this vaccine</li> <li>Should follow a booster at 2 years of age</li> </ul>
12 months	Hep-A1	<b>Hepatitis A:</b> <ul style="list-style-type: none"> <li>Single dose for live attenuated H2—strain Hep—A vaccine</li> <li>Two doses for all killed Hep—A vaccines are recommended now</li> </ul>
15 months	MMR2 Varicella1 PCV Booster	<b>MMR:</b> <ul style="list-style-type: none"> <li>The 2nd dose must follow in 2nd year of life</li> <li>However, it can be given at anytime 4 to 8 weeks after the 1st dose</li> </ul> <b>Varicella:</b> The risk of breakthrough varicella is lower if given 15 months onwards
16–18 months	DTwP B1/ DTaP B1 IPV B1 Hib B1	The first booster (4th dose) may be administered as early as age 12 months, provided at least 6 months have elapsed since the third dose <b>DTP:</b> <ul style="list-style-type: none"> <li>First and second boosters should preferably be of DTwP</li> <li>Considering a higher reactogenicity of DTwP, DTaP can be considered for the boosters</li> </ul>
18 months	Hep A2	<b>Hepatitis A:</b> The 2nd dose for killed vaccines; only single dose for live attenuated H2 – strain vaccine
2 years	Typhoid booster	<ul style="list-style-type: none"> <li>Either Typbar – TCV or Vi – polysaccharide (Vi – P5) can be employed as booster</li> <li>Typhoid revaccination every 3 years, if Vi–polysaccharide vaccine is used</li> <li>Need of revaccination following a booster of Typbar–TCV not yet determined</li> </ul>
4–6 years	DTwP B2/ DTaP B2 OPV 3 Varicella 2 Typhoid booster	<b>Varicella:</b> The 2nd dose can be given at anytime 3 months after the 1st dose

Contd...

Contd...

I. IAP recommended vaccines for routine use		
Age (completed weeks/ months/years)	Vaccines	Comments
10–12 years	Tdap/Td HPV	<b>Tdap:</b> is preferred to Td followed by Td every 10 years <b>HPV:</b> <ul style="list-style-type: none"> <li>Only 2 doses of either of the two HPV vaccines for adolescent/preadolescent girls aged 9 – 14 years;</li> <li>For girls 15 years and older, and immune compromised individuals, 3 doses are recommended</li> </ul>
Age (completed weeks/ months/years)	Vaccines	Comments
		<ul style="list-style-type: none"> <li>For 2 dose schedule, the minimum interval between doses should be 6 months</li> <li>For 3 dose schedule, the doses can be administered at 0, 1–2 (depending on brands) and 6 months</li> </ul>
II. IAP recommended vaccines for high-risk* children (vaccines under special circumstances):		
<ol style="list-style-type: none"> <li>1. Influenza vaccine</li> <li>2. Meningococcal vaccine</li> <li>3. Japanese encephalitis vaccine</li> <li>4. Cholera vaccine</li> <li>5. Rabies vaccine</li> <li>6. Yellow fever vaccine</li> <li>7. Pneumococcal polysaccharide vaccine (PPSV 23)</li> </ol>		

**\*High-risk category of children:**

- Congenital or acquired immunodeficiency (including HIV infection)
- Chronic cardiac, pulmonary (including asthma treated with prolonged high-dose oral corticosteroids), hematologic, renal (including nephritic syndrome), liver disease and diabetes mellitus
- Children on long-term steroids, salicylates, immunosuppressive or radiation therapy
- Diabetes mellitus, cerebrospinal fluid leak, cochlear implant, malignancies
- Children with functional / anatomic asplenia / hyposplenia
- During disease outbreaks
- Laboratory personnel and healthcare workers
- Travelers
- Children having pets in home
- Children perceived with higher threat of being bitten by dogs such as hostellers, risk of stray dog menace while going outdoor



**Table 3.3** IAP Recommended Immunization Schedule for Children Aged 0–18 years (with range)

Vaccine/Age	Birth	6 wk	10 wk	14 wk	18 wk	6 mo	9 mo	12 mo	15 mo	18 mo	19–23 mo	2–3 yr	4–6 yr	7–10 yr	11–12 yr	13–18 yr
BCG	BCG															
Hep B	Hep B1	Hep B2				Hep B3										
Polio	OPV0	IPV1	IPV2	IPV3		OPV1	OPV2	IPVB1					OPV3			
DTP		DTP1	DTP2	DTP3					DTPB1				DTPB2			
Tdap														Tdap		
Hib		Hib1	Hib2	Hib3					Hib booster							
Pneumococcal		PCV1	PCV2	PCV3					PCV booster				PCV			
PPSV23												PPSV				
Rotavirus		RV1	RV2	RV3												
Measles							Measles									
MMR								MMR1					MMR2			
Varicella									VAR1				VAR2			

Contd...

# Immunization in Clinical Practice

Immunization has become an important part of the clinical practice in pediatrics. The last few years have seen some exciting developments in the field of immunization. This book *Immunization in Clinical Practice* is thoroughly revised and updated with the objectives of providing the concise, reader-friendly and evidence-based scientific knowledge within a single book that incorporates both the science and art of immunization. A successful book is the sum of the contributions provided by its expert contributors. All the contributors of this book are genuine experts in the field of vaccinology. The strength of this book is knowledge, hard work and experience of its contributors. This book should serve as a reference book, especially for the practicing pediatricians, family physicians, postgraduate students and paramedics.

**Naveen Thacker** is a Practicing Pediatrician at Gandhidham, Gujarat, India. He was the President of the Indian Academy of Pediatrics (IAP) in the year 2007. He is also the President of the Asia Pacific Pediatric Association for the period 2016–18. He is a GAVI Board Member and also the Coordinator of Development in the International Pediatric Association (IPA). He is also a member of the Technical Advisory Group on Immunization of IPA. He is the recipient of several awards, including the Outstanding Asian Pediatrician Award, Fellowship of IAP and Rotary International Regional Award for Polio-Free World. He is wellknown for his work for polio eradication and pulse polio campaign. He has been a faculty for INDVAC Vaccinology course since 2010. He was the first to design and implement the Basic Newborn Care and Resuscitation Program in India—the biggest-ever child survival project in the world.



**Nitin K Shah** is a Consultant Pediatrician and Pediatric Hematologist/Oncologist at PD Hinduja National Hospital, Mumbai, Maharashtra, India, as well as an honorary Consultant Pediatric Hematologist/Oncologist at BJ Wadia Hospital for Children, Mumbai. He was the President of the Indian Academy of Pediatrics in the year 2006. He was the Co-Chair of IAP Committee on Immunization in 2005–06, and Advisor to the Committee in 2012–13. He is one of the editors of the prestigious *IAP Textbook on Vaccines*. He was the Editor-in-Chief of the IAP specialty series books, namely *Hematology*, *Rational Antimicrobials*, *HIV*, *Pediatric Quiz*, *Cardiology*, *Gastroenterology*, and *Intensive Care*.



**Abhay K Shah** is a Senior Consultant Pediatrician of Ahmedabad, Gujarat, with 30 years of private practice experience. He did his MBBS in 1979, from NHL Municipal Medical College with a Gold Medal in the subject of Medicine. He secured first rank in Dped (1982) and passed his MD (Ped) with a Gold Medal in 1983 from KM School of Postgraduate Medicine and Research, Ahmedabad.

Infectious diseases, vaccinology and community pediatrics are his special areas of interest. He is the Past President of AOP, Ahmedabad; Past President of AOP, Gujarat; Honorary Secretary of IAP ID CHAPTER, for the year 2012–13; and National Chairperson of IAP ID CHAPTER 2015. He has rendered his services as a resource person and national trainer for a number of IAP modules such as SOV, ASOV, IAPVAC, PSPID, ASPP, RTI GEM, RAP, IAP APT, IAP-RNTCP Tuberculosis, etc.



**Alok Gupta** is a Pediatrician and a Counselor at Pediatric Specialties Clinic, Jaipur, Rajasthan, India. He did his MBBS (1984); MD (Ped Med) (1988) from SMS Medical College, Jaipur. He was an Assistant Professor in the Department of Pediatric Medicine, Mahatma Gandhi Medical College and Hospital, Jaipur. He is an expert resource person (vaccinology) and technical expert, safe injection practices and bio-medical waste disposal (SIP-BMW); national IAP trainer: SOV, PSPID, SIP, Adolescent Care in Office Practice, EXODIAM, How do I Manage? Promoting Emotional Intelligence in Children (PEICH) and Nutrition Education Program of IAP. He is the member of IAP National Task Force on Prevention of Obesity in Children and Consultative Group, and Rational Antibiotic Therapy. He has been working extensively with the WHO and other NGOs for removing lead from paints, and other lead products to eliminate chronic lead poisoning in India. He is also working for use of 'Safe Plastics Only' in food and pharmaceutical industry to make the products safe for human consumption and also to eliminate environmental hazards associated with the use of plastics in general.



Available at all medical bookstores  
or buy online at [www.jaypeebrothers.com](http://www.jaypeebrothers.com)



**JAYPEE BROTHERS**  
**Medical Publishers (P) Ltd.**  
[www.jaypeebrothers.com](http://www.jaypeebrothers.com)

Join us on [facebook.com/JaypeeMedicalPublishers](https://www.facebook.com/JaypeeMedicalPublishers)

Shelving Recommendation  
**PEDIATRICS**

